An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients

{ 'indexed': {'date-parts': [[2022, 4, 19]], 'date-time': '2022-04-19T12:41:17Z', 'timestamp': 1650372077487}, 'reference-count': 29, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 4, 19]], 'date-time': '2022-04-19T00:00:00Z', 'timestamp': 1650326400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 4, 19]], 'date-time': '2022-04-19T00:00:00Z', 'timestamp': 1650326400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [{'name': 'Kris Gopalakrishnan'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'short-container-title': ['Sci Rep'], 'published-print': {'date-parts': [[2022, 12]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Indomethacin, a non-steroidal anti-inflammatory drug ' '(NSAID), has been presented as a broad-spectrum antiviral agent. This randomised clinical ' 'trial in a hospital setting evaluated the efficacy and safety of this drug in RT-PCR-positive ' 'coronavirus disease 2019 (COVID-19) patients. A total of 210 RT-PCR-positive COVID-19 ' 'patients who provided consent were allotted to the control or case arm, based on block ' 'randomisation. The control arm received standard of care comprising paracetamol, ivermectin, ' 'and other adjuvant therapies. The patients in the case arm received indomethacin instead of ' 'paracetamol, with other medications retained. The primary endpoint was the development of ' 'hypoxia/desaturation with SpO<jats:sub>2</jats:sub>\u2009≤\u200993, while time to become ' 'afebrile and time for cough and myalgia resolution were the secondary endpoints. The results ' 'of 210 patients were available, with 103 and 107 patients in the indomethacin and paracetamol ' 'arms, respectively. We monitored patient profiles along with everyday clinical parameters. In ' 'addition, blood chemistry at the time of admission and discharge was assessed. As no one in ' 'either of the arms required high-flow oxygen, desaturation with a SpO<jats:sub>2</jats:sub> ' 'level of 93 and below was the vital goal. In the indomethacin group, none of the 103 patients ' 'developed desaturation. On the other hand, 20 of the 107 patients in the paracetamol arm ' 'developed desaturation. Patients who received indomethacin also experienced more rapid ' 'symptomatic relief than those in the paracetamol arm, with most symptoms disappearing in half ' 'the time.\xa0In addition, 56 out of 107 in the paracetamol arm had fever on the seventh day, ' 'while no patient in the indomethacin group had fever. Neither arm reported any adverse event. ' 'The fourteenth-day follow-up revealed that the paracetamol arm patients had faced several ' 'discomforts; indomethacin arm patients mostly complained only of tiredness. Indomethacin is a ' 'safe and effective drug for treating patients with mild and moderate covid-19.\n' '</jats:p>', 'DOI': '10.1038/s41598-022-10370-1', 'type': 'journal-article', 'created': {'date-parts': [[2022, 4, 19]], 'date-time': '2022-04-19T12:08:21Z', 'timestamp': 1650370101000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised ' 'Covid-19 patients'], 'prefix': '10.1038', 'volume': '12', 'author': [ {'given': 'Rajan', 'family': 'Ravichandran', 'sequence': 'first', 'affiliation': []}, {'given': 'Surapaneni Krishna', 'family': 'Mohan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Suresh Kumar', 'family': 'Sukumaran', 'sequence': 'additional', 'affiliation': []}, {'given': 'Devakumar', 'family': 'Kamaraj', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sumetha Suga', 'family': 'Daivasuga', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Samson Oliver Abraham Samuel', 'family': 'Ravi', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Sivakumar', 'family': 'Vijayaraghavalu', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Ramarathnam Krishna', 'family': 'Kumar', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 4, 19]]}, 'reference': [ { 'issue': '3', 'key': '10370_CR1', 'doi-asserted-by': 'publisher', 'first-page': '155', 'DOI': '10.1038/s41579-020-00468-6', 'volume': '19', 'author': 'P V’kovski', 'year': '2021', 'unstructured': 'V’kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. ' 'Coronavirus biology and replication: implications for SARS-CoV-2. Nat. ' 'Rev. Microbiol. 19(3), 155–170 (2021).', 'journal-title': 'Nat. Rev. Microbiol.'}, { 'issue': '7816', 'key': '10370_CR2', 'doi-asserted-by': 'publisher', 'first-page': '459', 'DOI': '10.1038/s41586-020-2286-9', 'volume': '583', 'author': 'DE Gordon', 'year': '2020', 'unstructured': 'Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals ' 'targets for drug repurposing. Nature 583(7816), 459–468 (2020).', 'journal-title': 'Nature'}, { 'issue': '1', 'key': '10370_CR3', 'doi-asserted-by': 'publisher', 'first-page': '5', 'DOI': '10.1002/med.21728', 'volume': '41', 'author': 'X Wang', 'year': '2021', 'unstructured': 'Wang, X. & Guan, Y. COVID-19 drug repurposing: A review of computational ' 'screening methods, clinical trials, and protein interaction assays. Med. ' 'Res. Rev. 41(1), 5–28 (2021).', 'journal-title': 'Med. Res. Rev.'}, { 'issue': '1', 'key': '10370_CR4', 'doi-asserted-by': 'publisher', 'first-page': '134', 'DOI': '10.1038/s41392-021-00558-8', 'volume': '6', 'author': 'M-M Zhao', 'year': '2021', 'unstructured': 'Zhao, M.-M. et al. Cathepsin L plays a key role in SARS-CoV-2 infection ' 'in humans and humanized mice and is a promising target for new drug ' 'development. Signal Transd. Target. Therapy 6(1), 134 (2021).', 'journal-title': 'Signal Transd. Target. Therapy'}, { 'key': '10370_CR5', 'first-page': '10', 'volume': '2020', 'author': 'CP Gomes', 'year': '2020', 'unstructured': 'Gomes, C. P. et al. Cathepsin L in COVID-19: from pharmacological ' 'evidences to genetics. Front. Cell. Infect. Microbiol. 2020, 10 (2020).', 'journal-title': 'Front. Cell. Infect. Microbiol.'}, { 'key': '10370_CR6', 'doi-asserted-by': 'publisher', 'first-page': '90', 'DOI': '10.1016/j.cegh.2020.07.006', 'volume': '9', 'author': 'A Frediansyah', 'year': '2021', 'unstructured': 'Frediansyah, A., Tiwari, R., Sharun, K., Dhama, K. & Harapan, H. ' 'Antivirals for COVID-19: a critical review. Clin. Epidemiol. Glob. ' 'Health 9, 90–98 (2021).', 'journal-title': 'Clin. Epidemiol. Glob. Health'}, { 'issue': '21', 'key': '10370_CR7', 'doi-asserted-by': 'publisher', 'first-page': '12359', 'DOI': '10.1021/acs.jmedchem.0c00606', 'volume': '63', 'author': 'C Gil', 'year': '2020', 'unstructured': 'Gil, C. et al. COVID-19: drug targets and potential treatments. J. Med. ' 'Chem. 63(21), 12359–12386 (2020).', 'journal-title': 'J. Med. Chem.'}, { 'issue': '7', 'key': '10370_CR8', 'doi-asserted-by': 'publisher', 'first-page': '2085', 'DOI': '10.1007/s10067-020-05190-5', 'volume': '39', 'author': 'M Soy', 'year': '2020', 'unstructured': 'Soy, M. et al. Cytokine storm in COVID-19: pathogenesis and overview of ' 'anti-inflammatory agents used in treatment. Clin. Rheumatol. 39(7), ' '2085–2094 (2020).', 'journal-title': 'Clin. Rheumatol.'}, { 'issue': '10', 'key': '10370_CR9', 'first-page': '1', 'volume': '9403', 'author': 'DE Gordon', 'year': '2020', 'unstructured': 'Gordon, D. E. et al. Comparative host-coronavirus protein interaction ' 'networks reveal pan-viral disease mechanisms. Science 9403(10), 1–38 ' '(2020).', 'journal-title': 'Science'}, { 'issue': '8', 'key': '10370_CR10', 'doi-asserted-by': 'publisher', 'first-page': '1021', 'DOI': '10.1177/135965350601100803', 'volume': '11', 'author': 'C Amici', 'year': '2006', 'unstructured': 'Amici, C. et al. Indomethacin has a potent antiviral activity against ' 'SARS coronavirus. Antivir. Ther. 11(8), 1021–1030 (2006).', 'journal-title': 'Antivir. Ther.'}, { 'key': '10370_CR11', 'first-page': '8', 'volume': '12', 'author': 'T Xu', 'year': '2020', 'unstructured': 'Xu, T., Gao, X., Wu, Z., Selinger, D. W. & Zhou, Z. Indomethacin has a ' 'potent antiviral activity against SARS CoV-2 in vitro and canine ' 'coronavirus in vivo. bioRxiv 12, 8 (2020).', 'journal-title': 'bioRxiv'}, { 'key': '10370_CR12', 'unstructured': 'Napolitano, F., Gambardella, G., Carrella, D., Gao, X., & di Bernardo, ' 'D. Computational drug repositioning and elucidation of mechanism of ' 'action of compounds against SARS-CoV-2 (2020)'}, { 'key': '10370_CR13', 'first-page': '188', 'volume': '98', 'author': 'N Raghav', 'year': '1993', 'unstructured': 'Raghav, N., Kamboj, R. C. & Singh, H. Effect of some steroidal and ' 'non-steroidal anti-inflammatory drugs on purified goat brain cathepsin ' 'L. Indian J. Med. Res. B Biomed. Res. Other Infect. Dis. 98, 188–192 ' '(1993).', 'journal-title': 'Indian J. Med. Res. B Biomed. Res. Other Infect. Dis.'}, { 'issue': '9', 'key': '10370_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1391', 'DOI': '10.1111/cmi.12446', 'volume': '17', 'author': 'C Amici', 'year': '2015', 'unstructured': 'Amici, C. et al. Inhibition of viral protein translation by indomethacin ' 'in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell. ' 'Microbiol. 17(9), 1391–1404 (2015).', 'journal-title': 'Cell. Microbiol.'}, { 'issue': '2', 'key': '10370_CR15', 'doi-asserted-by': 'publisher', 'first-page': '379', 'DOI': '10.1042/BJ20111236', 'volume': '443', 'author': 'C Brunelli', 'year': '2012', 'unstructured': 'Brunelli, C. et al. The non-steroidal anti-inflammatory drug ' 'indomethacin activates the eIF2αkinase PKR, causing a translational ' 'block in human colorectal cancer cells. Biochem. J. 443(2), 379–386 ' '(2012).', 'journal-title': 'Biochem. J.'}, { 'key': '10370_CR16', 'doi-asserted-by': 'publisher', 'first-page': '104370', 'DOI': '10.1016/j.jcv.2020.104370', 'volume': '127', 'author': 'F Liu', 'year': '2020', 'unstructured': 'Liu, F. et al. Prognostic value of interleukin-6, C-reactive protein, ' 'and procalcitonin in patients with COVID-19. J. Clin. Virol. 127, 104370 ' '(2020).', 'journal-title': 'J. Clin. Virol.'}, { 'key': '10370_CR17', 'doi-asserted-by': 'publisher', 'first-page': '155151', 'DOI': '10.1016/j.cyto.2020.155151', 'volume': '133', 'author': 'M Mahmudpour', 'year': '2020', 'unstructured': 'Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S. & Nabipour, I. ' 'COVID-19 cytokine storm: the anger of inflammation. Cytokine 133, 155151 ' '(2020).', 'journal-title': 'Cytokine'}, { 'issue': '8', 'key': '10370_CR18', 'doi-asserted-by': 'publisher', 'first-page': '1017', 'DOI': '10.1016/S0531-5565(00)00128-5', 'volume': '35', 'author': 'AMJ Bour', 'year': '2000', 'unstructured': 'Bour, A. M. J., Westendorp, R. G., Laterveer, J., Bollen, E. L. E. & ' 'Remarque, E. Interaction of indomethacin with cytokine production in ' 'whole blood. Potential mechanism for a brain-protective effect. Exp. ' 'Gerontol. 35(8), 1017–1024 (2000).', 'journal-title': 'Exp. Gerontol.'}, { 'issue': '1', 'key': '10370_CR19', 'doi-asserted-by': 'publisher', 'first-page': '91', 'DOI': '10.1097/00007890-199201000-00017', 'volume': '53', 'author': 'MR First', 'year': '1992', 'unstructured': 'First, M. R., Schroeder, T. J., Hariharan, S., Alexander, J. W. & ' 'Weiskittel, P. The effect of indomethacin on the febrile response ' 'following OKT3 therapy1. Transplantation 53(1), 91–93 (1992).', 'journal-title': 'Transplantation'}, { 'issue': '3', 'key': '10370_CR20', 'doi-asserted-by': 'publisher', 'first-page': '486', 'DOI': '10.1016/S0272-6386(12)80906-1', 'volume': '24', 'author': 'WJ Gaughan', 'year': '1994', 'unstructured': 'Gaughan, W. J., Francos, B. B., Dunn, S. R., Francos, G. C. & Burke, J. ' 'F. A retrospective analysis of the effect of indomethacin on adverse ' 'reactions to orthoclone OKT3 in the therapy of acute renal allograft ' 'rejection. Am. J. Kidney Dis. 24(3), 486–490 (1994).', 'journal-title': 'Am. J. Kidney Dis.'}, { 'issue': '7', 'key': '10370_CR21', 'first-page': '42', 'volume': '119', 'author': 'R Ravichandran', 'year': '2021', 'unstructured': 'Ravichandran, R. et al. Use of indomethacin in COVID-19 patients: ' 'experience from two medical centres. J. Indian Med. Assoc. 119(7), 42–46 ' '(2021).', 'journal-title': 'J. Indian Med. Assoc.'}, { 'key': '10370_CR22', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.5455/IJMRCR.LOW-DOSE-INDOMETHACIN', 'volume': '2020', 'author': 'R Rajan', 'year': '2020', 'unstructured': 'Rajan, R., Subramanian, S. & Clark, C. Low dose indomethacin for ' 'symptomatic treatment of COVID-19. Int. J. Med. Rev. Case Rep. 2020, 1 ' '(2020).', 'journal-title': 'Int. J. Med. Rev. Case Rep.'}, { 'issue': '10', 'key': '10370_CR23', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.4236/oalib.1106860', 'volume': '07', 'author': 'A Kanakaraj', 'year': '2020', 'unstructured': 'Kanakaraj, A. & Ravichandran, R. Low dose indomethacin in the outpatient ' 'treatment of COVID-19 in kidney transplant recipients—a case series. ' 'OALib. 07(10), 1–8 (2020).', 'journal-title': 'OALib.'}, { 'issue': '1', 'key': '10370_CR24', 'doi-asserted-by': 'publisher', 'first-page': '26', 'DOI': '10.1186/1471-2288-4-26', 'volume': '4', 'author': 'M Saghaei', 'year': '2004', 'unstructured': 'Saghaei, M. Random allocation software for parallel group randomized ' 'trials. BMC Med. Res. Methodol. 4(1), 26 (2004).', 'journal-title': 'BMC Med. Res. Methodol.'}, { 'issue': '2', 'key': '10370_CR25', 'first-page': '67', 'volume': '1', 'author': 'T Sakpal', 'year': '2010', 'unstructured': 'Sakpal, T. Sample size estimation in clinical trial. Perspect. Clin. ' 'Res. 1(2), 67 (2010).', 'journal-title': 'Perspect. Clin. Res.'}, { 'issue': '1', 'key': '10370_CR26', 'doi-asserted-by': 'publisher', 'first-page': '469', 'DOI': '10.1080/13102818.2020.1775118', 'volume': '34', 'author': 'G Momekov', 'year': '2020', 'unstructured': 'Momekov, G. & Momekova, D. Ivermectin as a potential COVID-19 treatment ' 'from the pharmacokinetic point of view: antiviral levels are not likely ' 'attainable with known dosing regimens. Biotechnol. Biotechnol. Equip. ' '34(1), 469–474 (2020).', 'journal-title': 'Biotechnol. Biotechnol. Equip.'}, { 'issue': '5532', 'key': '10370_CR27', 'doi-asserted-by': 'publisher', 'first-page': '69', 'DOI': '10.1136/bmj.1.5532.69', 'volume': '1', 'author': 'P Donnelly', 'year': '1967', 'unstructured': 'Donnelly, P., Lloyd, K. & Campbell, H. Indomethacin in rheumatoid ' 'arthritis: an evaluation of its anti-inflammatory and side effects. BMJ ' '1(5532), 69–75 (1967).', 'journal-title': 'BMJ'}, { 'key': '10370_CR28', 'unstructured': 'Indomethacin drug usage statistics, United States, 2018 [Internet]. ' '2018. https://clincalc.com/DrugStats/Drugs/Indomethacin'}, { 'issue': '3', 'key': '10370_CR29', 'doi-asserted-by': 'publisher', 'first-page': '102', 'DOI': '10.1007/s40495-021-00257-6', 'volume': '7', 'author': 'M Alkotaji', 'year': '2021', 'unstructured': 'Alkotaji, M. & Al-Zidan, R. N. Indomethacin: can it counteract ' 'bradykinin effects in COVID-19 patients?. Curr. Pharmacol. Rep. 7(3), ' '102–106 (2021).', 'journal-title': 'Curr. Pharmacol. Rep.'}], 'container-title': ['Scientific Reports'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41598-022-10370-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-10370-1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-10370-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 4, 19]], 'date-time': '2022-04-19T12:09:09Z', 'timestamp': 1650370149000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-022-10370-1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 4, 19]]}, 'references-count': 29, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['10370'], 'URL': 'http://dx.doi.org/10.1038/s41598-022-10370-1', 'relation': {}, 'ISSN': ['2045-2322'], 'issn-type': [{'value': '2045-2322', 'type': 'electronic'}], 'subject': ['Multidisciplinary'], 'published': {'date-parts': [[2022, 4, 19]]}, 'assertion': [ { 'value': '14 December 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '6 April 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 April 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '6413'}